Shalabh Gupta

Globavir Biosciences, Inc. develops therapeutics and diagnostics for the treatment of infectious diseases. The American company was founded in 2011 by Shalabh Gupta, who has been the CEO since 2011.

The Indus Entrepreneurs is a non-profit organization. It provides mentoring, networking, education and funding to entrepreneurs. The company was founded in 1992 and is headquartered in Santa Clara, CA.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™.

Phenomenome Discoveries, Inc. provides human health research tools to discover metabolite biomarkers. Its services include discovery, analytics, informatics, collaborators and analytical services. The company was founded by John Hyshka and Dayan B. Goodenowe in 2000 and is headquartered in Saskatoon, Canada.

Part of Sorrento Therapeutics, Inc., Biocycive, Inc. is a biotechnology company focused on oncology. The company is based in Los Altos, CA. The company was founded in 2010 by Shalabh Gupta. Biocycive was acquired by Sorrento Therapeutics, Inc. on January 31, 2015 for $160 million.